DC Chemicals Limited
China
Product Name: Vecabrutinib
Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/500mg
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

1510829-06-7

1510829-06-7 structure

1510829-06-7 structure

Name: Vecabrutinib
Chemical Name: vecabrutinib
CAS Number: 1510829-06-7
Molecular Formula: C₂₂H₂₄ClF₄N₇O₂
Molecular Weight: 529.918
Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK Btk
Create Date: 2018-09-01 06:19:35
Modify Date: 2024-01-03 18:38:40
Vecabrutinib is a potent, noncovalent BTK and ITK inhibitor, with Kd of 0.3 nM and 2.2 nM, respectively; Vecabrutinib shows an IC50 of 24 nM for ITK.

Name	vecabrutinib
Synonyms	PQ7O0OB5GU (3R,3'R,4'S)-1'-(6-Amino-5-fluoro-4-pyrimidinyl)-3-{[3-chloro-5-(trifluoromethyl)phenyl]amino}-2-oxo-1,3'-bipiperidine-4'-carboxamide vecabrutinib [1,3'-Bipiperidine]-4'-carboxamide, 1'-(6-amino-5-fluoro-4-pyrimidinyl)-3-[[3-chloro-5-(trifluoromethyl)phenyl]amino]-2-oxo-, (3R,3'R,4'S)-

Description	Vecabrutinib is a potent, noncovalent BTK and ITK inhibitor, with Kd of 0.3 nM and 2.2 nM, respectively; Vecabrutinib shows an IC50 of 24 nM for ITK.
Related Catalog	Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Btk Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Itk Research Areas >> Cancer
Target	IC50: 24 nM (ITK)[2] Kd: 0.3 nM (BTK), 2.2 nM (ITK)[1]
In Vitro	Vecabrutinib inhibits pBTK in human whole blood with an average IC50 of 50 nM. Vecabrutinib inhibits WT and C481S BTK with similar IC50s (pBTK IC50s: WT BTK 2.9 nM, C481S BTK 4.4 nM)[1]. In a recombinant kinase assay, IC50s of Vecabrutinib against WT BTK and C481S BTK are 4.6 nM and 1.1 nM. Vecabrutinib retains activity against the mutated BTK variant. Vecabrutinib is six times more potent than ibrutinib and greater than 640 times more potent than acalabrutinib against C481S BTK. Vecabrutinib demonstrates dose-dependent inhibition of BTK in primary patient CLL cells comparable to ibrutinib via immunoblot for BTK phosphorylation. Vecabrutinib decreases viability of primary CLL cells in the presence of HS5 stromal protection by 5.5%[2].
In Vivo	Vecabrutinib has good oral bioavailability in rat and dog (%F ≥ 40%) and a terminal half-life of 5 to 6 hours. Vecabrutinib is well tolerated with continuous drug levels and at exposures much greater than those achieved for ibrutinib[1].
References	[1]. Minke E. Binnerts, et al. Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation. Molecular Cancer Therapeutics. December 2015 Volume 14, Issue 12 Supplement 2 [2]. Catherine A. Fabian, et al. Abstract 1207: SNS-062 demonstrates efficacy in chronic lymphocytic leukemia in vitro and inhibits C481S mutated Bruton tyrosine kinase. Cancer Research July 2017 Volume 77, Issue 13 Supplement

Density	1.5±0.1 g/cm3
Boiling Point	776.0±60.0 °C at 760 mmHg
Molecular Formula	C₂₂H₂₄ClF₄N₇O₂
Molecular Weight	529.918
Flash Point	423.1±32.9 °C
Exact Mass	529.161621
LogP	3.13
Vapour Pressure	0.0±2.7 mmHg at 25°C
Index of Refraction	1.621
Storage condition	2-8℃